Use of Vitamin K Antagonists and Brain Volumetry in Older Adults: Preliminary Results From the GAIT Study

2015 ◽  
Vol 63 (10) ◽  
pp. 2199-2202 ◽  
Author(s):  
Cedric Annweiler ◽  
Soraya Denis ◽  
Guillaume Duval ◽  
Guylaine Ferland ◽  
Robert Bartha ◽  
...  
Keyword(s):  
Older Adults ◽  
Vitamin K ◽  
Vitamin K Antagonists ◽  
Preliminary Results ◽  
Brain Volumetry ◽  
Gait Study

Use of Vitamin K Antagonists and Brain Morphological Changes in Older Adults: An Exposed/Unexposed Voxel-Based Morphometric Study

2018 ◽  
Vol 45 (1-2) ◽  
pp. 18-26 ◽  
Author(s):  
Antoine Brangier ◽  
Sébastien Celle ◽  
Frédéric Roche ◽  
Olivier Beauchet ◽  
Guylaine Ferland ◽  
...  
Keyword(s):  
Older Adults ◽  
White Matter ◽  
Vitamin K ◽  
Morphological Changes ◽  
Vitamin K Antagonists ◽  
Statistical Parametric Mapping ◽  
Morphometric Study ◽  
Intracranial Volume ◽  
Brain Physiology ◽  
Vitamin K Cycle

Background: Vitamin K antagonists (VKAs) are commonly used for their role in haemostasis by interfering with the vitamin K cycle. Since vitamin K also participates in brain physiology, this voxel-based morphometric study aimed to determine whether the duration of exposure to VKAs correlated with focal brain volume reduction in older adults. Methods: In this exposed/unexposed (1: 2) study nested within the GAIT (Gait and Alzheimer Interactions Tracking) cohort, 18 participants exposed to VKA (mean age 75 ± 5 years; 33.3% female; mean exposure 2,122 ± 1,799 days) and 36 matched participants using no VKA (mean age 75 ± 5 years; 33.3% female) underwent MRI scanning of the brain. Cortical grey and white matter volumes were automatically segmented using statistical parametric mapping. Age, gender, educational level, history of atrial fibrillation, type of MRI, and total intracranial volume were included as covariables. Results: The duration of exposure to VKA correlated inversely across the whole brain with the subvolumes of two clusters in the grey matter (right frontal inferior operculum and right precuneus) and one cluster in the white matter (left middle frontal gyrus). In contrast, the grade of white matter hyperintensities did not differ according to the use of VKA. Conclusion: We found focal atrophies in older adults exposed to VKA. These findings provide new insights elucidating the effects of VKAs on brain health and function in older adults.

scholarly journals Vitamin K Antagonists and Cognitive Function in Older Adults: The Three-City Cohort Study

2015 ◽  
Vol 71 (10) ◽  
pp. 1356-1362 ◽  
Author(s):  
Guylaine Ferland ◽  
Catherine Feart ◽  
Nancy Presse ◽  
Simon Lorrain ◽  
Fabienne Bazin ◽  
...  
Keyword(s):  
Older Adults ◽  
Cohort Study ◽  
Cognitive Function ◽  
Vitamin K ◽  
Vitamin K Antagonists

scholarly journals Thromboembolism in Older Adults

2021 ◽  
Vol 7 ◽  
Author(s):  
Peter L. Gross ◽  
Noel C. Chan
Keyword(s):  
Older Adults ◽  
Venous Thromboembolism ◽  
Vitamin K ◽  
Older Patients ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Very Elderly ◽  
Direct Acting ◽  
Risk And Benefit ◽  
Direct Acting Oral Anticoagulants

Arterial and venous thromboembolism are both more common in older adults. The use of anticoagulants, the mainstay to prevent thromboembolism, requires consideration of the balance between risk and benefit. Such consideration is even more important in the very elderly in whom the risk of anticoagulant-related bleeding and thrombosis are higher. This review will focus on the challenges of implementing and managing anticoagulant therapy in older patients in an era when the options for anticoagulants include not only vitamin K antagonists (VKAs), but also direct-acting oral anticoagulants (DOACs).

Intracranial calcifications under vitamin K antagonists or direct oral anticoagulants: Results from the French VIKING study in older adults

Maturitas ◽  
2020 ◽  
Vol 132 ◽  
pp. 35-39 ◽  
Author(s):  
Gaëlle Annweiler ◽  
Mathieu Labriffe ◽  
Pierre Ménager ◽  
Guylaine Ferland ◽  
Antoine Brangier ◽  
...  
Keyword(s):  
Older Adults ◽  
Vitamin K ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Intracranial Calcifications

scholarly journals Vitamin K Antagonists and Cognitive Decline in Older Adults: A 24-Month Follow-Up

Nutrients ◽  
2018 ◽  
Vol 10 (6) ◽  
pp. 666 ◽  
Author(s):  
Antoine Brangier ◽  
Guylaine Ferland ◽  
Yves Rolland ◽  
Jennifer Gautier ◽  
Catherine Féart ◽  
...  
Keyword(s):  
Older Adults ◽  
Cognitive Decline ◽  
Vitamin K ◽  
Vitamin K Antagonists

Idiopathic venous thrombosis

2006 ◽  
Vol 26 (01) ◽  
pp. 52-54 ◽  
Author(s):  
P. A. Kyrle
Keyword(s):  
Chronic Disease ◽  
Venous Thrombosis ◽  
Vitamin K ◽  
Clinical Benefit ◽  
Plasma Levels ◽  
Vitamin K Antagonists ◽  
Antithrombin Deficiency ◽  
Optimal Duration ◽  
Risk Of Treatment

SummaryVenous thrombosis is a chronic disease with a recurrence rate of approximately 30% within 5-8 years. The optimal duration of secondary thromboprophylaxis in these patients entails balancing the risk of recurrence against the risk of treatment-associated bleeding. There is agreement that patients with a first idiopathic venous thrombosis should receive vitamin K antagonists for at least 3-6 months. Convincing trials showing a clinical benefit in terms of morbidity or mortality with respect to expansion of anticoagulation beyond 6 months are lacking. Nevertheless, some subgroups of patients with venous thrombosis may benefit from indefinite anticoagulation. Thus, patients with antithrombin deficiency, combined or homozygous defects, more than one unprovoked episode of thrombosis, the lupus anticoagulant or high factor VIII plasma levels are good candidates for long-term prevention.

Spectrophotometric Assays of Prothrombin in Plasma of Patients Using Oral Anticoagulants

1979 ◽  
Vol 42 (04) ◽  
pp. 1296-1305 ◽  
Author(s):  
R M Bertina ◽  
W van der Marel-van Nieuwkoop ◽  
E A Loeliger
Keyword(s):  
Prothrombin Time ◽  
Vitamin K ◽  
Oral Anticoagulation ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Factor Xa ◽  
Factor V ◽  
Anticoagulant Treatment ◽  
Factor Ii ◽  
K Deficiency

SummaryTwo spectrophotometric assays for prothrombin have been developed and compared with a one stage coagulant and an immunological assay. One of these assays (called the XAPC assay) uses a combination of factor Xa, phospholipid, Ca2+ and factor V as activator of prothrombin, and measures only normal prothrombin. The second (the ECAR assay) uses Echis carinatus venom as activator. This assay measures both normal prothrombin and PIVKA II (protein induced by vitamin K antagonists/absence). Combination of the results obtained by the XAPC and ECAR assays provides rapid and reliable information on the degree of “subcarboxylation” of prothrombin (oral anticoagulation, vitamin K deficiency).For patients on long term anticoagulant treatment the prothrombin time (Thrombotest) shows better correlation with the ratio prothrombin/prothrombin plus PIVKA II (XAPC/ ECAR) than with the factor II concentration. For patients starting the anticoagulant treatment there is no correlation between the Thrombotest time and the XAPC/ECAR ratio.It seems doubtful that (a) spectrophotometric factor II assay(s) will be as useful as the prothrombin time in the control of oral anticoagulation.

Sign in / Sign up

Export Citation Format

Share Document